Acute Crit Care.  2022 Aug;37(3):339-346. 10.4266/acc.2022.00675.

The fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City

• Tandon P
• Leibner E
• Hackett A
• Maguire K
• Leonardi K
• Levin MA
• Kohli-Seth R

• KMID: 2535297
• DOI: http://doi.org/10.4266/acc.2022.00675

Abstract

Background
We aim to describe the demographics and outcomes of patients with severe disease with the Omicron variant. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continues to mutate, and the availability of vaccines and boosters continue to rise, it is important to understand the health care burden of new variants. We analyze patients admitted to intensive care units (ICUs) in a large Academic Health System during New York City’s fourth surge beginning on November 27, 2021.
Methods
All patients admitted to an ICU were included in the primary analysis. Key demographics and outcomes were retrospectively compared between patients stratified by vaccination status. Univariate and multivariate logistic regression was used to identify risk factors for in-hospital mortality.
Results
In-hospital mortality for all admitted patients during the fourth wave was significantly lower than in previous waves. However, among patients requiring intensive care, in-hospital mortality was high across all levels of vaccination status. In a multivariate model older age was associated with increased in-hospital mortality, vaccination status of overdue for booster was associated with decreased in hospital mortality, and vaccination status of up-to-date with vaccination showed a trend to reduced mortality.
Conclusions
In-hospital mortality of patients with severe respiratory failure from coronavirus disease 2019 (COVID-19) remains high despite decreasing overall mortality. Vaccination against SARS-CoV-2 was protective against mortality. Vaccination remains the best and safest way to protect against serious illness and death from COVID-19. It remains unclear that any other treatment will have success in changing the natural history of the disease.

Keyword

COVID-19; Mortality; Omicron

Figure

• 

  Figure 1. (A) Coronavirus disease 2019 (COVID-19) admissions to Mount Sinai Health System. (B) Trend in unadjusted COVID-19 death rate over time. HFNC: high-flow nasal cannula; NIPPV: non-invasive positive pressure ventilation.

Reference

1. NYC Health. COVID-19: data on trends and totals [Internet]. New York (NY): NYC Health;2022. [cited 2022 Apr 1]. Available from: https://www1.nyc.gov/site/doh/covid/covid-19-data-totals.page.

2. Centers for Disease Control and Prevention. Omicron variant: what you need to know [Internet]. Atlanta (GA): Centers for Disease Control and Prevention;2022. [cited 2022 Apr 1]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html.

3. NYC Health. COVID-19: data on vaccines [Internet]. New York (NY): NYC Health;2022. [cited 2022 Apr 1]. Available from: https://www1.nyc.gov/site/doh/covid/covid-19-data-vaccines.page#trends.

4. Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Ojeda Saavedra M, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol. 2022; 192:642–52.

5. Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. Am J Pathol. 2022; 192:320–31.

6. Hyman JB, Leibner ES, Tandon P, Egorova NN, Bassily-Marcus A, Kohli-Seth R, et al. Timing of intubation and in-hospital mortality in patients with coronavirus disease 2019. Crit Care Explor. 2020; 2:e0254.

7. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19: final report. N Engl J Med. 2020; 383:1813–26.

8. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384:693–704.

9. Bradbury CA, McQuilten Z. Anticoagulation in COVID-19. Lancet. 2022; 399:5–7.

10. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020; 383:2333–44.

11. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020; 41:355–9.

12. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022; 386:1397–408.

13. Barbaro RP, MacLaren G, Boonstra PS, Combes A, Agerstrand C, Annich G, et al. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the International Extracorporeal Life Support Organization Registry. Lancet. 2021; 398:1230–8.

14. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine: United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:1922–4.

15. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. medRxiv. [Preprint]. 2022 [cited 2022 Apr 1]. Available from: https://doi.org/10.1101/069187 https://doi.org/10.1101/2022.01.11.22269045.

16. Tandon P, Leibner E, Ahmed S, Acquah SO, Kohli-Seth R. Comparing seasonal trends in coronavirus disease 2019 patient data at a quaternary hospital in New York City. Crit Care Explor. 2021; 3:e0381.

17. Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance: one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71:217–23.

18. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021; 385:585–94.

19. Wise J. COVID-19: delta variant doubles risk of hospital admission compared with alpha variant, study shows. BMJ. 2021; 374:n2152.